Novoeight® (turoctocog alfa) receives approval from the FDA
16 October 2013 | By Novo Nordisk
“The approval of Novoeight® marks an important step in offering a new alternative for people with haemophilia A..."
List view / Grid view
News
Gilead’s single tablet HIV Regimen Stribild® demonstrates durable viral suppression through three years of therapy
16 October 2013 | By Gilead
Long-term data in treatment-naïve patients highlight Stribild’s sustained efficacy, safety and tolerability profile...
Amgen announces appointment of Greg C. Garland to Board of Directors
16 October 2013 | By Amgen
Mr. Garland will serve on the Governance and Nominating Committee and the Audit Committee of the Board...
Janssen submits marketing authorisation application to European Medicines Agency
15 October 2013 | By Johnson & Johnson
...for a fixed-dose combination tablet of HIV-1 medicine Darunavir with Cobicistat...
AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
15 October 2013 | By AstraZeneca
Additional investment in and collaboration with ADC Therapeutics...
Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval
14 October 2013 | By Boehringer Ingelheim
Nintedanib*, when added to chemotherapy, is the first lung cancer treatment that extended patient survival...
Roche to invest 800 million Swiss francs in global biologic medicine manufacturing network
14 October 2013 | By Roche
Investment to help meet rising demand for licensed biologics and expected pipeline growth...
Lundbeck research projects secure funding from The Michael J. Fox Foundation
14 October 2013 | By H. Lundbeck A/S
The Michael J. Fox Foundation has donated 5.5 million kroner to two Danish research projects in Parkinson's disease...
New study shows oral nutritional supplement use in pediatric inpatients is associated with decreases in length of hospital stay, costs
11 October 2013 | By Abbott
"Malnutrition in children is associated with poor health outcomes and this is especially important in the hospitalized child..."
AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
11 October 2013 | By AstraZeneca
AstraZeneca announced that it has entered into an agreement to co-promote, an innovative oral therapy for the treatment of patients with prostate cancer...
Teva accelerates cost reduction program
10 October 2013 | By Teva Pharmaceutical Industries Ltd
$2.0 billion in annual cost savings by the end of 2017 including $1.0 billion by the end of 2014...
Campaign marks new brand direction focused on lip health and product innovation
9 October 2013 | By Pfizer
The brand’s latest innovation provides eight hours of moisture and contains advanced ingredient...
Pfizer announces top-line results of the first two of Five Phase 3 clinical trials of Tofacitinib in adults with moderate-to-severe chronic plaque psoriasis
9 October 2013 | By Pfizer Inc.
“We are excited to see progress in our development program in psoriasis..."
Gilead to stop Phase 3 Study 116 of Idelalisib in chronic lymphocytic leukemia early because of positive risk benefit
9 October 2013 | By Gilead
"We are pleased that idelalisib has shown a clinically meaningful benefit for patients..."
Many adults aged 60-plus plan to take steps to avoid flu but not other potentially preventable diseases such as shingles
8 October 2013 | By Merck
The survey revealed the importance of physicians and pharmacists in encouraging vaccination...
